MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cullinan Therapeutics, Inc. - Common Stock (NQ:CGEM)

12.44 +0.25 (+2.05%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cullinan Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-978, a Novel CD19xCD3 T cell Engager, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
From Cullinan Oncology, Inc.
Via GlobeNewswire
News headline image
Cullinan Oncology to Participate in Upcoming Investor Conferences
From Cullinan Oncology, Inc.
Via GlobeNewswire
News headline image
Analyst Ratings for Cullinan Oncology ↗
 
Via Benzinga
News headline image
Analyst Expectations for Cullinan Oncology's Future ↗
 
Via Benzinga
News headline image
Expert Ratings for Cullinan Oncology ↗
 
Via Benzinga
News headline image
4 Analysts Have This to Say About Cullinan Oncology ↗
 
Via Benzinga
News headline image
A Look Into Healthcare Sector Value Stocks ↗
 
Via Benzinga
News headline image
Overview Of Value Stocks In The Healthcare Sector ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2023 ↗
 
Via Benzinga
News headline image
Why Shares of Cullinan Oncology Jumped This Week ↗
The company's presentation at a conference got the attention of analysts and investors. 
Via The Motley Fool
News headline image
Cullinan Oncology to Present First Monotherapy Clinical Data for CLN-619, a Novel Anti-MICA/B Antibody, at ASCO 2023
From Cullinan Oncology, Inc.
Via GlobeNewswire
News headline image
Cullinan Oncology Provides Corporate Update and Reports First Quarter 2023 Financial Results
From Cullinan Oncology, Inc.
Via GlobeNewswire
News headline image
What 4 Analyst Ratings Have To Say About Cullinan Oncology ↗
 
Via Benzinga
5 Value Stocks In The Healthcare Sector ↗
 
Via Benzinga
News headline image
Cullinan Oncology to Present First Clinical Data Evaluating Novel Anti-MICA/B Antibody, CLN-619, in Patients with Advanced Solid Tumors at ASCO 2023
From Cullinan Oncology, Inc.
Via GlobeNewswire
News headline image
Cullinan Oncology to Participate in Stifel’s 2023 Targeted Oncology Days
From Cullinan Oncology, Inc.
Via GlobeNewswire
News headline image
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-617, a Novel Fusion Protein Harnessing IL-2 and IL-12 Cytokines
From Cullinan Oncology, Inc.
Via GlobeNewswire
News headline image
Cullinan Oncology to Present New Preclinical Data for CLN-619 and CLN-617 at the 2023 American Association for Cancer Research Annual Meeting
From Cullinan Oncology, Inc.
Via GlobeNewswire
News headline image
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
From Cullinan Oncology, Inc.
Via GlobeNewswire
News headline image
Cullinan Oncology to Participate in Cowen’s 43rd Annual Health Care Conference
From Cullinan Oncology, Inc.
Via GlobeNewswire
News headline image
Week In Review: China Biopharmas Announce Three Out-Licensing Deals Totaling $2 Billion ↗
Jiangsu Hengrui Pharma out-licensed US rights for a novel small molecule EZH2 inhibitor in a $706 million agreement with Treeline Biosciences of Connecticut. Hengrui will receive an upfront payment of... 
Via Talk Markets
News headline image
Cullinan Oncology Licenses U.S. Rights to the First Clinical-Stage B7H4 x 4-1BB Bispecific Immune Activator from Harbour BioMed
From Cullinan Oncology, Inc.
Via GlobeNewswire
News headline image
Cullinan Oncology to Participate in the Guggenheim 5th Annual Oncology Conference and the SVB Securities Global Biopharma Conference
From Cullinan Oncology, Inc.
Via GlobeNewswire
News headline image
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Cullinan Oncology, Inc.
Via GlobeNewswire
News headline image
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-978, a Novel T-Cell Engager for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
From Cullinan Oncology, Inc.
Via GlobeNewswire
News headline image
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Cullinan Oncology, Inc.
Via GlobeNewswire
News headline image
5 Value Stocks To Watch In The Healthcare Sector ↗
 
Via Benzinga
News headline image
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Cullinan Oncology, Inc.
Via GlobeNewswire
News headline image
Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2022 Financial Results
From Cullinan Oncology, Inc.
Via GlobeNewswire
News headline image
Cullinan Oncology Announces the Appointment of David P. Ryan, M.D. to its Board of Directors
From Cullinan Oncology, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story